ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.49
-0.43%
US Tech 100
19,430.40
0.14%
S&P 500
5,487.03
0.25%
US Dollar vs CAD
1.37125
0.05%
Bitcoin
65,102.33
0.21%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) News

ARVN

Arvinas (ARVN)

Arvinas Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARVN
DateTimeSourceHeadlineSymbolCompany
06/18/20244:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
06/18/20244:51PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
06/18/20243:55PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
06/17/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
06/17/20246:00AMGlobeNewswire Inc.Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific OfficerNASDAQ:ARVNArvinas Inc
06/03/20243:30PMGlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
05/31/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
05/30/20243:52PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
05/23/20248:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
05/23/20244:00PMGlobeNewswire Inc.Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual CongressNASDAQ:ARVNArvinas Inc
05/16/20245:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
05/16/20245:00AMGlobeNewswire Inc.Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)NASDAQ:ARVNArvinas Inc
05/09/20243:42PMGlobeNewswire Inc.Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressNASDAQ:ARVNArvinas Inc
05/07/20243:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARVNArvinas Inc
05/07/20246:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
05/07/20246:00AMGlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
05/02/20246:00AMGlobeNewswire Inc.Arvinas to Present at Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
04/24/20243:30PMGlobeNewswire Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNASDAQ:ARVNArvinas Inc
04/11/20246:00AMGlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNASDAQ:ARVNArvinas Inc
03/18/20243:40PMGlobeNewswire Inc.Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerNASDAQ:ARVNArvinas Inc
03/04/20246:00AMGlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
02/27/20245:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20245:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20245:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20245:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
02/27/20243:46PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARVNArvinas Inc
02/27/20246:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
02/27/20246:00AMGlobeNewswire Inc.Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
02/20/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
02/20/20243:05PMGlobeNewswire Inc.Arvinas Announces Chief Financial Officer TransitionNASDAQ:ARVNArvinas Inc
 Showing the most relevant articles for your search:NASDAQ:ARVN

Your Recent History

COIN
ZEITBTC
BOV
SNAG11
Suno Agro Fiagro Im Unica
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved